Please assess the completion status of the following clinical trial:

Trial Title: Effects of Probiotic on Inflammation and Microbiota in Patients With NASH

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years of age or older~* Capable of giving informed consent~* Diagnosed with NAFLD as defined by the American Association for the Study of Liver Diseases (AASLD) who are treated or seen solely at the outpatient clinic at the Department of Hepatology at 400 Community Drive in Manhasset NY~Exclusion Criteria:~* Cirrhosis~* Absence of secondary causes of hepatic fat accumulation including:~* Excessive alcohol consumption~* Hepatitis C~* Wilson's Disease~* Lipodystrophy~* Starvation~* Parenteral Nutrition~* Abetalipoproteinemia~* Specific Medications: Amiodarone, Methotrexate, Tamoxifen, Corticosteroids, Valproate, Anti-retroviral agents)~* Reye's Syndrome~* HELLP Syndrome~* Inborn errors of metabolism (LCAT deficiency, cholesterol ester storage disease, Wolman disease)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Probiotic administration (Type: EXPERIMENTAL): After baseline collection of serum and fecal microbiota, each subject will be administered the probiotic formulation VSL#3 450 Billion CFU Twice daily for 8 weeks. Serum and fecal microbiota will again be collected at the end of the intervention and compared with baseline with each subject serving as his or her own control.

Based on this trial design, predict the completion outcome and termination type (if applicable).